The Biomedical Prevention Program has 41 investigators from 16 departments and four schools with a research base of $6.8 million in annual direct funding, Including $4.4 million from the NCI. Its members published 1092 papers over this grant period, of which 37% were intra-programmatic and 39% ware interprogrammatic collaborations. 155 of these publications were in high impact journals (Impact factor >7.51). The objective of the Biomedical Prevention Program is to reduce the morbidity and mortality caused by cancer through preventing the occurrence and improving survival with earlier diagnosis. The alms of the program are: 1) To build and to support organ-focused, vertically Integrated research projects that encompass environmental and genetic approaches In order to Identify individuals and populations a high risk for future neoplastic progression;2) To discover and validate biomarkers for risk assessment and early detection of common, high mortality cancers through the integration of high throughput genomic, proteomic, and biotechnologies;3) To Identify and determine preventive efficacy of Interventions with pharmacologic and nutritional tools with the aim of delaying or reversing neoplastic progression in individuals identified at high risk;and 4) To develop and validate new biostatistical methodologies to study population clusters and surrogate endpoints. The populations targeted for these programs include the general population and special at-risk groups.
All of the research in the Biomedical Prevention Program has direct cancer relevance and covers the spectrum of research Including basic pharmacology of chemopreventive agents, gene discovery and risk modeling, proteomic studies that are directly applied to early detection, pharmacologic interventions Including Phase II, investigator initiated trials of chemopreventive agents, pharmacogenetic studies of preventive agents and outcomestudies including biomarkers, survival and prevention of treatment symptoms.
|Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36|
|Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13|
|Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67|
|Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65|
|Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46|
|Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47|
|Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21|
|Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15|
|Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (Î±/Î²) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957|
|Di Girolamo, Daniela; Ambrosio, Raffaele; De Stefano, Maria A et al. (2016) Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. J Clin Invest 126:2308-20|
Showing the most recent 10 out of 1165 publications